Predictive toxicology approaches for small molecule oncology drugs

Toxicologic Pathology

Volumn 38, Issue 1, 2010, Pages 148-164

  Maziasz, T ^a   Kadambi, V J ^a   Silverman, L ^a   Fedyk, E ^a   Alden, C L ^a  

^a NONE

Author keywords

Cancer; Carcinogenesis; Discovery pathology; Oncology; Pharmaceutical development products; Preclinical research and development; Toxicologic pathology

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITOR; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; BORTEZOMIB; COMPLEMENTARY RNA; CYTOSTATIC AGENT; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ENZYME; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; IRINOTECAN; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; OXALIPLATIN; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; POTASSIUM CHANNEL HERG; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RECEPTOR; SMALL INTERFERING RNA; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; VACCINE; XENOBIOTIC AGENT;

ADVANCED CANCER; ASTHENIA; BLOOD TOXICITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DATA BASE; DOSIMETRY; DRUG CYTOTOXICITY; DRUG INFORMATION; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROPATHY; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TOXICOKINETICS; ANIMAL; DRUG APPROVAL; DRUG DEVELOPMENT; FACTUAL DATABASE; METHODOLOGY; NEOPLASM; PATHOLOGY; TOXICOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DATABASES, FACTUAL; DRUG DISCOVERY; HUMANS; INVESTIGATIONAL NEW DRUG APPLICATION; MAXIMUM TOLERATED DOSE; NEOPLASM STAGING; NEOPLASMS; TOXICOLOGY;

EID: 77952304596     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623309356448     Document Type: Review

References (70)

1. Aronov, A. M. (2008). Tuning out of hERG. Curr Opin Drug Discov Devel 11, 128-140
2. Atterwill, C. K., and Wing, M. G. (2002). In vitro preclinical lead optimisation technologies (PLOTs) in pharmaceutical development. Toxicol Lett 127, 143-151
3. Balani, S. K., Miwa, G. T., Gan, L. S., Wu, J. T., and Lee, F. W. (2005). Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection. Curr Top Med Chem 5, 1033-1038
4. Bolon, B. (2004). Genetically engineered animals in drug discovery and development: a maturing resource for toxicologic research. Basic Clin Pharmacol Toxicol 95, 154-161
5. Boyle P, Levin, B., ed. 2008. World Cancer Report 2008. Lyon, France: World Health Organization. Available at: www.who.int. Accessed 2009.
6. Caldwell, G. W., Ritchie, D. M., Masucci, J. A., Hageman, W., and Yan, Z. (2001). The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. Curr Top Med Chem 1, 353-366
7. Campillos, M., Kuhn, M., Gavin, A. C., Jensen, L. J., and Bork, P. (2008). Drug target identification using side-effect similarity. Science 321, 263-266
8. Castoldi, R. E., Pennella, G., Saturno, G. S., Grossi, P., Brughera, M., and Venturi, M. (2007). Assessing and managing toxicities induced by kinase inhibitors. Curr Opin Drug Discov Devel 10, 53-57.
9. Christel, M. D. (2009). From Pipeline to market. Pipelines bulk up as industry shakes up R&D, a surge in clinical projects spurs hope. R&D Directions 15, 12-89.
10. Clark, J. W., Eder, J. P., Ryan, D., Lathia, C., and Lenz, H. J. (2005). Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11, 5472-5480
11. Davies, S. P., Reddy, H., Caivano, M., and Cohen, P. (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351, 95-105.
12. DiMasi, J. A., and Grabowski, H. G. (2007). Economics of new oncology drug development. J Clin Oncol 25, 209-216
13. Dorato, M. A., and Engelhardt, J. A. (2005). The no-observed-adverse- effectlevel in drug safety evaluations: use, issues, and definition(s). Regul Toxicol Pharmacol 42, 265-274
14. Fedorov, O., Marsden, B., Pogacic, V., Rellos, P., Muller, S., Bullock, A. N., Schwaller, J., Sundstrom, M., and Knapp, S. (2007). A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A 104, 20523-20528
15. Force, T., Krause, D. S., and Van Etten, R. A. (2007). Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7, 332-344 (Pubitemid 46652481)
16. Gibbs, J. B. (2000). Mechanism-based target identification and drug discovery in cancer research. Science 287, 1969-1973
17. Goldstein, D. M.,Gray,N. S., and Zarrinkar, P. P. (2008).High-throughput kinase profiling as a platform for drug discovery. Nat Rev Drug Discov 7, 391-397
18. Guner, O. F. (2000). Pharmacophore Perception, Development, and Use in Drug Design (IUL Biotechnology Serie;, 2), O. F. Guner, ed. pp. xv-xix. International University Line, La Jolla, CA.
19. th ed. McGraw-Hill Professional, New York, NY.
20. Haystead, T. A. (2006). The purinome, a complex mix of drug and toxicity targets. Curr Top Med Chem 6, 1117-1127
21. Houck, K. A., and Kavlock, R. J. (2008). Understanding mechanisms of toxicity: insights from drug discovery research. Toxicol Appl Pharmacol 227, 163-178
22. Hsieh, F. Y., Tengstrand, E., Lee, J. W., Li, L. Y., Silverman, L., Riordan, B., Miwa, G., Milton, M., Alden, C., and Lee, F. (2007). Drug safety evaluation through biomarker analysis-a toxicity study in the cynomolgus monkey using an antibody-cytotoxic conjugate against ovarian cancer. Toxicol Appl Pharmacol 224, 12-18.
23. Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., Decrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., Greene, N., Huang, E., Krieger-Burke, T., Loesel, J., Wager, T., Whiteley, L., and Zhang, Y. (2008). Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 18, 4872-4875
24. Iglehart, J. D., and Silver, D. P. (2009). Synthetic lethality-a new direction in cancer-drug development. N Engl J Med 361, 189-191
25. Illanes, O., Anderson, S., Niesman, M., Zwick, L., and Jessen, B. A. (2006). Retinal and peripheral nerve toxicity induced by the administration of a pan-cyclin dependent kinase (cdk) inhibitor in mice. Toxicologic pathology 34, 243-248
26. Jackson Lab (2009). The Jackson Lab Mice Database. Available at: http://www.jaxmice.jax.org/strain. Accessed 2009.
27. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., and Thun, M. J. (2009). Cancer statistics, 2009. CA Cancer J Clin 59, 225-249
28. Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., Faraoni, R., Floyd, M., Hunt, J. P., Lockhart, D. J., Milanov, Z. V., Morrison, M. J., Pallares, G., Patel, H. K., Pritchard, S., Wodicka, L. M., and Zarrinkar, P. P. (2008). A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26, 127-132
29. Kerkela, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., Rosenzweig, A., Salomon, R. N., Van Etten, R. A., Alroy, J., Durand, J. B., and Force, T. (2006). Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12, 908-916
30. Knapp, M., Bellamacina, C., Murray, J. M., and Bussiere, D. E. (2006). Targeting cancer: the challenges and successes of structure-based drug design against the human purinome. Curr Top Med Chem 6, 1129-1159
31. Kola, I., and Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3, 711-715
32. Kramer, J. A., Sagartz, J. E., and Morris, D. L. (2007). The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov 6, 636-649
33. Lacouture, M. E. (2006). Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6, 803-812
34. Lang, W., Caldwell, G. W., Li, J., Leo, G. C., Jones, W. J., and Masucci, J. A. (2007). Biotransformation of geldanamycin and 17-allylamino-17- demethoxygeldanamycin by human liver microsomes: reductive versus oxidative metabolism and implications. Drug Metab Dispos 35, 21-29.
35. Larkin, J. M., and Eisen, T. (2006). Kinase inhibitors in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol 60, 216-226 (Pubitemid 44709619)
36. Leeson, P. D., and Springthorpe, B. (2007). The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6, 881-890
37. Lesko, L. J., Rowland, M., Peck, C. C., and Blaschke, T. F. (2000). Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res 17, 1335-1344 (Pubitemid 32109484)
38. Lewis, R. W., Billington, R., Debryune, E., Gamer, A., Lang, B., and Carpanini, F. (2002). Recognition of adverse and nonadverse effects in toxicity studies. Toxicol Pathol 30, 66-74.
39. Liebler, D. C., and Guengerich, F. P. (2005). Elucidating mechanisms of druginduced toxicity. Nat Rev Drug Discov 4, 410-420
40. Loerzel, V. W., and Dow, K. H. (2003). Cardiac toxicity related to cancer treatment. Clin J Oncol Nurs 7, 557-562
41. Marchetti, S., and Schellens, J. H. (2007). The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br J Cancer 97, 577-581
42. Marshall, J. (2006). Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107, 1207-1218
43. Merlot, C. (2008). In silico methods for early toxicity assessment. Curr Opin Drug Discov Devel 11, 80-85.
44. Newell, D. R., Silvester, J., McDowell, C., and Burtles, S. S. (2004). The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies. Eur J Cancer 40, 899-906.
45. Ng, R., Better, N., and Green, M. D. (2006). Anticancer agents and cardiotoxicity. Semin Oncol 33, 2-14.
46. Nowakowski, G. S., McCollum, A. K., Ames, M. M., Mandrekar, S. J., Reid, J. M., Adjei, A. A., Toft, D. O., Safgren, S. L., and Erlichman, C. (2006). A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 12, 6087-6093
47. O'Connell, D., and Roblin, D. (2006). Translational research in the pharmaceutical industry: from bench to bedside. Drug Discov Today 11, 833-838
48. Overington, J. P., Al-Lazikani, B., and Hopkins, A. L. (2006). How many drug targets are there? Nat Rev Drug Discov 5, 993-996
49. Patyna, S., Arrigoni, C., Terron, A., Kim, T.W., Heward, J. K., Vonderfecht, S. L., Denlinger, R., Turnquist, S. E., and Evering, W. (2008). Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors. Toxicol Pathol 36, 905-916
50. Paulson, S. K., and Maziasz, T. J. (2003). Role of metabolism and pharmacokinetics in the development of celecoxib. In Applications of Pharmacokinetics Principles in Drug Delivery (Krishna, R., ed.), pp. 405-25 Kluwer Academic/Plenum Publisher.
51. PhRMA (2009). Pharmaceutical Industry Report: Industry Profile 2009. Available at: http://www.phrma.org. Accessed 2009.
52. Ramiro-Ibanez, F., Trajkovic, D., and Jessen, B. (2005). Gastric and pancreatic lesions in rats treated with a pan-CDK inhibitor. Toxicol Pathol 33, 784-791
53. Rosa, D. D., Ismael, G., Lago, L. D., and Awada, A. (2008). Moleculartargeted therapies: lessons from years of clinical development. Cancer Treat Rev 34, 61-80.
54. Ryffel, B. (1997). Impact of knockout mice in toxicology. Crit Rev Toxicol 27, 135-154
55. Saijo, N. (2004). What are the reasons for negative phase III trials of moleculartarget-based drugs? Cancer Sci 95, 772-776
56. Saijo, N., Tamura, T., and Nishio, K. (2000). Problems in the development of target-based drugs. Cancer chemotherapy and pharmacology 46 Suppl, S43-45.
57. Sasseville, V. G., Lane, J. H., Kadambi, V. J., Bouchard, P., Lee, F. W., Balani, S. K., Miwa, G. T., Smith, P. F., and Alden, C. L. (2004). Testing paradigm for prediction of development-limiting barriers and human drug toxicity. Chem Biol Interact 150, 9-25.
58. Shanholtz, C. (2001). Acute life-threatening toxicity of cancer treatment. Crit Care Clin 17, 483-502.
59. Simbre, V. C., Duffy, S. A., Dadlani, G. H., Miller, T. L., and Lipshultz, S. E. (2005). Cardiotoxicity of cancer chemotherapy: implications for children. Paediatr Drugs 7, 187-202.
60. Smith, D. A., Johnson, D. E., and Park, B. K. (2006). Editorial overview: safety of drugs can never be absolute. Curr Opin Drug Discov Devel 9, 26-28.
61. Smith, D. A., and Schmid, E. F. (2006). Drug withdrawals and the lessons within. Curr Opin Drug Discov Devel 9, 38-46.
62. Supko, J. G., Hickman, R. L., Grever, M. R., and Malspeis, L. (1995). Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36, 305-315
63. Testa,B. (1995). Drug metabolism: The concept of toxophoric groups. In: Burger's medicinal chemistry and drug discovery, Vol 1: principles and practice. (M.E.Wolff, ed.) pp. 177-178. John Wiley and Sons, NewYork, New York.
64. Tomaszewski, J. E. (2004). Multi-species toxicology approaches for oncology drugs: the US perspective. Eur J Cancer 40, 907-913
65. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research (2000). Guidance for Industry: Pediatric Oncology Studies in Response to a Written Request. U.S. Food and Drug Administration, Rockville, MD.
66. Walker, I., and Newell, H. (2009). Do molecularly targeted agents in oncology have reduced attrition rates? Nat Rev Drug Discov 8, 15-16.
67. Wallace, K. B. (2008). Mitochondrial off targets of drug therapy. Trends Pharmacol Sci 29, 361-366
68. Yamamoto, D. S., and Viale, P. H. (2003). Cyclooxygenase-2: from arthritis treatment to new indications for the prevention and treatment of cancer. Clin J Oncol Nurs 7, 21-29.
69. Young, J. L., Jr., Ries, L. G., Silverberg, E., Horm, J. W., and Miller, R. W. (1986). Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer 58, 598-602.
70. Zambrowicz, B. P., and Sands, A. T. (2003). Knockouts model the 100 bestselling drugs-will they model the next 100? Nat Rev Drug Discov 2, 38-51.